Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-09

Study Completion Date

2024-04-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine with CpG 1018® Adjuvant Compared with rF1V Vaccine in Adults 18 to 55 Years of Age

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age

NCT07207408

Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis

RECRUITING PHASE2

Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

NCT04636697

SARS-CoV-2 Infection

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine

NCT05040789

COVID-19

WITHDRAWN PHASE3

Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.

NCT00291889

Tuberculosis (TB)

COMPLETED PHASE1

Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents

NCT05013983

COVID-19

WITHDRAWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Phase 2, randomized, active-controlled, observer-blind, multicenter trial of the immunogenicity, safety, and tolerability of rF1V vaccine with CpG 1018® adjuvant (rF1V-1018) compared with rF1V vaccine alone in adults. Approximately two hundred healthy adults 18 to 55 years of age will be enrolled to compare a two-dose regimen of rF1V-1018 with a three-dose regimen of rF1V vaccine alone. The study will be conducted in 2 parts (Part 1 and Part 2).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plague, Pneumonic Plague Vaccine-Preventable Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

rF1V-1018 co-administered (rF1V vaccine and CpG 1018® adjuvant co-administered)

Co-administration of rF1V vaccine and CpG 1018® adjuvant administered as 2 injections

Group Type EXPERIMENTAL

rF1V-1018

Intervention Type BIOLOGICAL

rF1V vaccine and CpG 1018® adjuvant

rF1V-bedside mix (rF1V vaccine and CpG 1018® adjuvant bedside mix)

Bedside mix of rF1V vaccine and CpG 1018® adjuvant administered administered as 2 injections

Group Type EXPERIMENTAL

rF1V-1018

Intervention Type BIOLOGICAL

rF1V vaccine and CpG 1018® adjuvant

rF1V vaccine only

rF1V vaccine administered as 3 injections

Group Type EXPERIMENTAL

rF1V vaccine

Intervention Type BIOLOGICAL

rF1V vaccine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rF1V-1018

rF1V vaccine and CpG 1018® adjuvant

Intervention Type BIOLOGICAL

rF1V vaccine

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults aged 18 to 55 years
* Healthy participants or participants with pre-existing medical conditions who are in a stable medical condition.

Pre-existing stable medical condition means a subject who: has full capacity of daily activity and no major medication modification within 3 months prior to Day 1; has not undergone surgical or minimally-invasive intervention or had any hospitalization/emergency room visit for the specific medical condition.

* Able to comply with the protocol schedule and procedures.
* Able and willing to provide written informed consent
* If female of child-bearing potential and heterosexually active, has practiced adequate contraception for 28 days prior to vaccination and has negative pregnancy tests just prior to vaccination and has agreed to continue adequate contraception until 28 days after last study injection. Adequate contraception is defined as a contraceptive method with a failure rate of \< 1% per year when used consistently and correctly and, when applicable, in accordance with the product label. Examples include the following:

* Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal
* Progestin-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable
* Intrauterine device (IUD) with or without hormonal release
* Vasectomized partner, provided he is the subject's sole partner and that he has received a medical assessment of the surgical success
* Credible self-reported history of heterosexual abstinence for at least 28 days prior to vaccine administration
* Female partner

Exclusion Criteria

* A history of plague disease or have previously received any plague vaccine.
* Active tuberculosis or other systemic infectious process.
* History of human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) infection, or positive test for antibody to HIV, HBV, or HCV
* History of autoimmune disorder
* History of sensitivity to any component of study vaccines
* Body mass index ≥ 30 kg/m2
* Has received the following prior to the injection:
* 14 days:
* COVID-19 vaccine
* Any inactivated vaccine
* 28 days:
* Any live vaccine
* Systemic corticosteroids (more than 3 consecutive days) or other immunomodulators or immunomodulators immune suppressive medication, with the exception of inhaled steroids
* Any other investigational medicinal agent
* 90 days:
* Immunoglobulins or any blood products
* Granulocyte or granulocyte-macrophage colony-stimulating factor
* Antisense oligonucleotides
* Drugs/investigational agents with very long half-lives (defined as ≥ 60 days)
* At any time: DNA plasmids or other genetic therapy intended to integrate permanently into host cells
* If female is pregnant (known before or established at the time of screening), breastfeeding, or planning a pregnancy
* Is undergoing chemotherapy or expected to receive chemotherapy during the study period; has a diagnosis of cancer within the last 5 years other than squamous cell or basal cell carcinoma of the skin
* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
* Oral temperature \>100.0°F at the time of vaccine administration.
* History of acute myocardial infarction (AMI) or documented coronary artery disease (CAD)

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes